IP-1:一种主要的Fos/Jun抑制剂,其活性通过酸化调节
1Laboratoire de Génétique Moléculaire, Eucaryotes du CNRS, Faculté de Médecine, Strasbourg, France.
Cell
|March 8, 1991
概括
一种新型的抑制蛋白 (IP-1) 通过阻止DNA结合来阻止转录因子AP-1的活性. 通过PKA的酸化使IP-1失活,这表明一种交叉对话机制可能调节基因转录.
科学领域:
- 分子生物学分子生物学
- 细胞信号传递 细胞信号传递
背景情况:
- 转录因子AP-1,是Fos和Jun蛋白的二分体,与TPA反应元素 (TREs) 结合,是蛋白激酶C信号的关键标.
- 在对各种刺激的反应中,AP-1活动对调节基因表达至关重要.
研究的目的:
- 识别和描述AP-1DNA结合活性的新型调节剂.
- 调查AP-1活动在不同细胞区域中调节的机制.
主要方法:
- 来自各种细胞类型的核和细胞质提取物被分析为AP-1调节器.
- 使用合成的Fos/Jun蛋白和核提取物进行了体外测试.
- 进行了涉及蛋白激酶A (PKA) 的酸化研究和使用合成的竞争试验.
主要成果:
- 鉴定出一个30-40kDa的抑制蛋白 (IP-1),存在于核和细胞质部分.
- IP-1 特别抑制了 AP-1 从核提取物和体外合成的 Fos/Jun 蛋白质中获得的 DNA 结合活性.
- IP-1的抑制功能需要其非酸化状态;PKA介导的酸化阻断了其活性,表明了潜在的交叉对话.
- 竞争实验表明IP-1与Fos和/或Jun的氨酸拉链区域相互作用.
结论:
- IP-1 作为AP-1 DNA 结合的负调节剂,调节其转录活性.
- 通过PKA介导的IP-1酸化为调节AP-1依赖转录提供了一个潜在的机制.
- IP-1 可能起到转录性抗原基因的作用,在控制细胞增殖和分化方面发挥作用.
更多相关视频
08:07Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
Published on: July 26, 2019
7.9K
06:56Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
856
相关概念视频
Feedback Inhibition
44.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
44.1K
Eukaryotic Transcription Inhibitors
9.1K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.1K
Phosphoinositides and PIPs
7.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.7K
Amplifying Signals via Enzymatic Cascade
15.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.3K
The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K
PI3K/mTOR/AKT Signaling Pathway
5.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.1K
